Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins

Virology

Volumn 474, Issue , 2015, Pages 10-18

  Qian, Jin ^a,b   Duff, Yann Le ^a   Wang, Yimeng ^a,b   Pan, Qinghua ^a   Ding, Shilei ^a,b   Zheng, Yi Min ^c   Liu, Shan Lu ^c   Liang, Chen ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c University of Missouri   (United States)

Author keywords

HIV; IFITM; SIV; Virus entry

Indexed keywords

AMPHOTERICIN B; INTERFERON INDUCED TRANSMEMBRANE 2 PROTEIN; INTERFERON INDUCED TRANSMEMBRANE 3 PROTEIN; INTERFERON INDUCED TRANSMEMBRANE PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; INTERFERON;

ANIMAL CELL; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; COS 1 CELL LINE; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA A VIRUS; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY; SEQUENCE HOMOLOGY; VERO CELL LINE;

PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; HEK293 CELLS; HIV; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLUENZA A VIRUS; INTERFERONS; LENTIVIRUSES, PRIMATE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SIMIAN IMMUNODEFICIENCY VIRUS; VERO CELLS; VIRUS INTERNALIZATION;

EID: 84909602803     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.10.015     Document Type: Article

References (34)

1. Amini-Bavil-Olyaee S., Choi Y.J., Lee J.H., Shi M., Huang I.C., Farzan M., Jung J.U. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013, 13(4):452-464.
2. Anafu A.A., Bowen C.H., Chin C.R., Brass A.L., Holm G.H. Interferon inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J. Biol. Chem. 2013, 288(24):17261-17271.
3. Bailey C.C., Huang I.C., Kam C., Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012, 8(9):e1002909.
4. Bailey C.C., Kondur H.R., Huang I.C., Farzan M. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J. Biol. Chem. 2013, 288(45):32184-32193.
5. Brass A.L., Huang I.C., Benita Y., John S.P., Krishnan M.N., Feeley E.M., Ryan B.J., Weyer J.L., van der Weyden L., Fikrig E., Adams D.J., Xavier R.J., Farzan M., Elledge S.J. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139(7):1243-1254.
6. Chesarino N.M., McMichael T.M., Hach J.C., Yount J.S. Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J. Biol. Chem. 2014, 289(17):11986-11992.
7. Desai T.M., Marin M., Chin C.R., Savidis G., Brass A.L., Melikyan G.B. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014, 10(4):e1004048.
8. Diamond M.S., Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 2013, 13(1):46-57.
9. Earp L.J., Delos S.E., Park H.E., White J.M. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 2005, 285:25-66.
10. Everitt A.R., Clare S., Pertel T., John S.P., Wash R.S., Smith S.E., Chin C.R., Feeley E.M., Sims J.S., Adams D.J., Wise H.M., Kane L., Goulding D., Digard P., Anttila V., Baillie J.K., Walsh T.S., Hume D.A., Palotie A., Xue Y., Colonna V., Tyler-Smith C., Dunning J., Gordon S.B., Gen I.I., Investigators M., Smyth R.L., Openshaw P.J., Dougan G., Brass A.L., Kellam P. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012, 484(7395):519-523.
11. Feeley E.M., Sims J.S., John S.P., Chin C.R., Pertel T., Chen L.M., Gaiha G.D., Ryan B.J., Donis R.O., Elledge S.J., Brass A.L. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011, 7(10):e1002337.
12. Harris L.D., Tabb B., Sodora D.L., Paiardini M., Klatt N.R., Douek D.C., Silvestri G., Muller-Trutwin M., Vasile-Pandrea I., Apetrei C., Hirsch V., Lifson J., Brenchley J.M., Estes J.D. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J. Virol. 2010, 84(15):7886-7891.
13. Hickford D., Frankenberg S., Shaw G., Renfree M.B. Evolution of vertebrate interferon inducible transmembrane proteins. BMC Genomics 2012, 13:155.
14. Huang I.C., Bailey C.C., Weyer J.L., Radoshitzky S.R., Becker M.M., Chiang J.J., Brass A.L., Ahmed A.A., Chi X., Dong L., Longobardi L.E., Boltz D., Kuhn J.H., Elledge S.J., Bavari S., Denison M.R., Choe H., Farzan M. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011, 7(1):e1001258.
15. Jacquelin B., Petitjean G., Kunkel D., Liovat A.S., Jochems S.P., Rogers K.A., Ploquin M.J., Madec Y., Barre-Sinoussi F., Dereuddre-Bosquet N., Lebon P., Le Grand R., Villinger F., Muller-Trutwin M. Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection. PLoS Pathog. 2014, 10(7):e1004241.
16. Jia R., Pan Q., Ding S., Rong L., Liu S.L., Geng Y., Qiao W., Liang C. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J. Virol. 2012, 86(24):13697-13707.
17. Jia R., Xu F., Qian J., Yao Y., Miao C., Zheng Y.M., Liu S.L., Guo F., Geng Y., Qiao W., Liang C. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol. 2014, 16(7):1080-1093.
18. Jiang D., Weidner J.M., Qing M., Pan X.B., Guo H., Xu C., Zhang X., Birk A., Chang J., Shi P.Y., Block T.M., Guo J.T. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J. Virol. 2010, 84(16):8332-8341.
19. Li K., Markosyan R.M., Zheng Y.M., Golfetto O., Bungart B., Li M., Ding S., He Y., Liang C., Lee J.C., Gratton E., Cohen F.S., Liu S.L. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013, 9(1):e1003124.
20. Lin T.Y., Chin C.R., Everitt A.R., Clare S., Perreira J.M., Savidis G., Aker A.M., John S.P., Sarlah D., Carreira E.M., Elledge S.J., Kellam P., Brass A.L. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 2013, 5(4):895-908.
21. Lu J., Pan Q., Rong L., He W., Liu S.L., Liang C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 2011, 85(5):2126-2137.
22. McClure M.O., Marsh M., Weiss R.A. Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J. 1988, 7(2):513-518.
23. Moffatt P., Gaumond M.H., Salois P., Sellin K., Bessette M.C., Godin E., de Oliveira P.T., Atkins G.J., Nanci A., Thomas G. Bril: a novel bone-specific modulator of mineralization. J. Bone Miner. Res. 2008, 23(9):1497-1508.
24. Mudhasani R., Tran J.P., Retterer C., Radoshitzky S.R., Kota K.P., Altamura L.A., Smith J.M., Packard B.Z., Kuhn J.H., Costantino J., Garrison A.R., Schmaljohn C.S., Huang I.C., Farzan M., Bavari S. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J. Virol. 2013, 87(15):8451-8464.
25. Perreira J.M., Chin C.R., Feeley E.M., Brass A.L. IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 2013, 425(24):4937-4955.
26. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6(5):409-421.
27. Siegrist F., Ebeling M., Certa U. The small interferon-induced transmembrane genes and proteins. J. Interf. Cytokine Res. 2011, 31(1):183-197.
28. Wakim L.M., Gupta N., Mintern J.D., Villadangos J.A. Enhanced survival of lung tissue-resident memory CD8(+) T cells during infection with influenza virus due to selective expression of IFITM3. Nat. Immunol. 2013, 14(3):238-245.
29. Warren C.J., Griffin L.M., Little A.S., Huang I.C., Farzan M., Pyeon D. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One 2014, 9(5):e96579.
30. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46(6):1896-1905.
31. Weidner J.M., Jiang D., Pan X.B., Chang J., Block T.M., Guo J.T. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 2010, 84(24):12646-12657.
32. Yount J.S., Karssemeijer R.A., Hang H.C. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J. Biol. Chem. 2012, 287(23):19631-19641.
33. Zhang Y.H., Zhao Y., Li N., Peng Y.C., Giannoulatou E., Jin R.H., Yan H.P., Wu H., Liu J.H., Liu N., Wang D.Y., Shu Y.L., Ho L.P., Kellam P., McMichael A., Dong T. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 2013, 4:1418.
34. Zhao X., Guo F., Liu F., Cuconati A., Chang J., Block T.M., Guo J.T. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc. Natl. Acad. Sci. USA 2014, 111(18):6756-6761.